ADC Therapeutics (ADCT) Operating Margin (2021 - 2026)

ADC Therapeutics (ADCT) posted quarterly Operating Margin of 121.07% for Q1 2026, up 251.0% year-on-year from 34.49% in Q1 2025, and up 35.78% on a QoQ basis from 188.52% in Q3 2025.

ADC Therapeutics (ADCT) Operating Margin (2021 - 2026) Analysis & Trends

ADC Therapeutics (ADCT) has reported Operating Margin for 6 consecutive years, with 121.07% the latest figure, recorded in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Operating Margin (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 16.51%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 38.10%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 17.83%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 31.68%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 ADC Therapeutics 189.60 Mn -41.41 Mn 17.38 Mn -121.07%

Historic Data

Download Data
DateValue
Mar 31, 2026 -121.07%
Sep 30, 2025 -188.52%
Jun 30, 2025 -234.34%
Mar 31, 2025 -123.58%
Sep 30, 2024 -192.61%
Jun 30, 2024 -166.81%
Mar 31, 2024 -186.19%
Sep 30, 2023 -249.42%
Jun 30, 2023 -205.62%
Mar 31, 2023 -271.55%
Sep 30, 2022 -4.08%
Jun 30, 2022 -401.43%
Mar 31, 2022 -86.81%
Sep 30, 2021 -439.58%
Jun 30, 2021 -1,874.52%